pujut | Joined since 2014-04-12

Investing Experience -
Risk Profile -





Blog Posts









Total comments
Past 30 days
Past 7 days

User Comments

1 month ago | Report Abuse

In its property sector note released on Monday (Aug 21), RHB IB assigned an “overweight” rating to the market, with “buy” calls for its top picks UEM Sunrise Bhd at a target price (TP) 92 sen, IOI Properties Group Bhd at a TP of RM1.46, and Matrix Concepts Holdings Bhd at RM1.75.


2022-12-23 09:58 | Report Abuse

Tq cosmos this is the 3rd u tlg saya..jatuh balik sy beli lagi yer hehehe


2022-12-22 15:20 | Report Abuse

Tolong jatuh banyak sikit nak beli balik dan tambah ni


2022-12-15 15:07 | Report Abuse

Ai leform bilalah kau nak bangun ni lama betul tdo


2022-11-17 08:56 | Report Abuse

Hrp2 hari ni lkl jatuh ke 37 sen n below


2022-11-17 08:54 | Report Abuse

Hrp2 hari ni thp jatuh ke 40 sen n below


2022-11-07 16:47 | Report Abuse

USA inflation data akn release pd 10/11 kalau data cantik sangat dan drama sama berulang smua jual IT stok then boleh beli balik murahlah..perlu sabar sikit


2022-11-04 15:35 | Report Abuse

Aii susahnya nak lepas 0.495...


2022-02-14 09:06 | Report Abuse

Cerita sama tp diulang2 hanya krn dyson kena saman oleh pekerja ata so bukak balik cerita sama nasib2 hehehe


2021-12-15 15:26 | Report Abuse

Bagus pls jatuh so can buy back


2021-12-08 10:39 | Report Abuse

Tq ata ambik profit dulu nanti dtg balik...


2021-08-30 20:28 | Report Abuse

Kena tengok berapa lama KJ ambik utk approve sinopharm..hrp lagi cepat dr yg lama


2021-06-28 11:43 | Report Abuse

Lepas egm terus tutup ingat jawab soalan online..kalau betul hrp dia jawablah later..


2021-06-28 01:42 | Report Abuse


Deal: Procurement of Sputnik V vaccine from two contract manufacturers in China, with capacity to produce between 312 and 960 million doses over 24 months.

Inked MoU with Russian Direct Investment Fund to manage contract manufacturers for the sovereign fund.

Status: The vaccine maker expects to receive approval from WHO within two months, and has to receive approval from Malaysia’s National Pharmaceutical Regulatory Agency (NPRA).


Deal: Entered into joint venture with E-MO Biology Inc for the development of Covid-19 vaccine derived from existing oral poliovirus vaccine.

Status: To commence production, distribution upon the completion of phase IV trial and approval from the US Food and Drug Administration (US FDA).


Deal: One of two companies that entered into Covid-19 vaccine supply agreements with the health ministry.

Entered into a purchase agreement with Sinovac for 14 million doses of ready-to-fill vaccine and to manufacture the doses domestically.

Received request for 7 million doses from state governments and GLCs.

Status: Expected to supply the federal government with 3.8 million Sinovac vaccine doses by end-June.

Expected to receive 10.4 million doses of Sinovac vaccine by end-August.

The group is able to produce 2 million doses a month


Deal: Entered into an agreement for the dealership and distribution of Sinopharm’s Covid-19 vaccine.

Inked MoU with Sabah state government for the procurement and import of Sinopharm’s vaccine.

Status: Awaiting delivery schedule from vaccine supplier.


Deal: Entered into a framework agreement for the commercialisation of Generex’s Ii-Key-SARS-CoV-2, for exclusive rights in Malaysia and several other countries in Southeast Asia. As a prerequisite it has to secure a pharmaceutical good distribution practice certification from the NPRA and register the product with the agency.

Status: The submission to NPRA is expected to be done by 2022/2023.

Generex has filed for a trademark application for the vaccine. Announced in January that it was preparing for a new drug application to US FDA.


Deal: Entered into an agreement with the Malaysian government for the supply of 6.4 million doses of Russia’s Sputnik V Covid-19 vaccine.

Status: The vaccine maker expects to receive approval from WHO within two months, and has to receive approval from NPRA.


Deal: Entered into a registration, manufacturing and commercialisation agreement to market and distribute China’s CanSino Biologics’ Covid-19 vaccine. It will establish a fill-and-finish facility for the vaccine.

Entered into a supply agreement with the health ministry for 3.5 million doses of CanSino’s vaccine.

Status: Received conditional approval from the Drug Control Authority for the vaccine for emergency use.


Deal: To distribute oral-based Covid-19 vaccine developed by US-based Vaxart Inc in Malaysia with Rinani Dynamic Sdn Bhd after obtaining licences and approval from the authorities in Malaysia.

Status: Vaxart to embark on phase II testing in mid-2021, will seek approval from NPRA upon obtaining approval from US FDA.


Deal: Entered into a partnership with SinoPhil Biotech for the provision of a Covid-19 vaccination programme in the Philippines.

Inked letter of intent with Anhui Zhifei Biopharmaceutical Co Ltd for the supply of initial 10 million doses of the latter’s Covid-19 vaccine as soon as the government gives approval for private market vaccination.

Status: Awaiting approval by the Philippine Food and Drug Administration.

Subject to Zhifei’s vaccine meeting all rules, regulations and licensing requirements imposed by NPRA.


Deal: Exclusive distributor for Shenzhen Kangtai Biological Products Co Ltd’s inactivated KConvac vaccine with a period of five years (renewable) for no less than 20 million doses yearly.

Received the first batch of Covid-19 vaccine.

Status: Obtained NPRA’s approval on June 3 for the Clinical Trial Import License. To roll out Phase III clinical trials in Malaysia.


2021-06-28 01:40 | Report Abuse

Shot in the arm for firms with Covid vaccine deals
Key challenge is the procurement of the product itself, says MIDF Research head

PETALING JAYA: As Malaysia’s Covid-19 vaccination programme picks up steam, companies that have ventured into the procurement and distribution of vaccines are set to benefit from such deals in the form of boosters to their income streams.

According to MIDF Research head Imran Yassin, the key challenge will be the procurement of the vaccine itself.

“However, it seems that, for now, this seems manageable. Besides, the varied sources of the vaccines will mitigate some of the concerns as we do not have to rely on one producer, which may lead to bottlenecks and delays in the delivery of vaccines,” he told SunBiz.

As Malaysia grapples with containing the Covid-19 pandemic, an accelerated vaccine rollout has been touted as a viable solution to its woes and set it on the right track towards economic reopening and recovery.

In developed economies such as the US and the UK, inoculation efforts have managed to turn around their struggles with the pandemic and brought them to the path of economic recovery.

The UK has logged an estimated 4.7 million Covid-19 cases to date, out of a population of 66.65 million. Since the rollout of vaccination, the country has eased curbs on certain sectors and sports events are allowed subject to conditions.

In recent weeks, the US has seen its 7-day average of new Covid-19 infections flatten to below 20,000 from a peak of 300,628 on Jan 8 after slightly more than half its population of 332 million have received at least one dose of vaccine.

With such empirical evidence, Imran opined that Malaysia’s economic recovery depends on the success of its vaccination programme. “Should herd immunity be achieved earlier, we believe that the country’s economic recovery will move in tandem and can also be achieved earlier,” he said.

Science, Technology, and Innovation Minister Khairy Jamaluddin, who serves as the National Covid-19 Immunisation Programme (NCIP) coordinating minister, announced on Thursday that the federal government is allowing state governments and private hospitals to purchase vaccines other than those used in the federal programme, provided they are approved by the World Health Organisation (WHO).

He said they could source vaccines from the same suppliers as the federal government, namely Sinovac and BioNtech-Pfizer, although the national vaccination programme’s orders will be fulfilled first.

Apart from Sinovac and BioNtech-Pfizer, WHO has approved AstraZaneca, Sinopharm, Serum Institute of India, Janssen and Moderna vaccines for emergency use.

In addition, to this, the NCIP has increased the number of mega vaccination centres. On June 21, the NCIP included Bukit Jalil Natinal Stadium in its list of mega vaccine centres. The stadium joins Kuala Lumpur Convention Centre, Setia City Convention Centre and three other mega vaccine centres that came online on June 7.

Imran views the efforts to ramp upvaccination in positive light and the immunisation objective is within reach. “The key now is to convince more rakyat to be inoculated, which is a shared responsibility and not just the government’s.”


2021-06-15 14:17 | Report Abuse

Hopefully next is Sinopharm


2021-06-15 14:17 | Report Abuse

PETALING JAYA: The Drug Control Authority (DCA) of Malaysia has approved the use of the Pfizer-BioNTech Covid-19 vaccine for those aged 12 and above, said Tan Sri Dr Noor Hisham Abdullah.

The Health director-general also said in a statement on Tuesday (June 15) that they gave conditional registration for the use of the CanSino and Johnson & Johnson vaccines, both of which only require one shot of the dose.


2021-06-03 13:28 | Report Abuse

Dalam sidang media hari ini, Khairy berkata, selagi vaksin itu sudah diluluskan Bahagian Regulatori Farmasi Negara (NPRA), kerajaan negeri bebas membelinya.

Mcm mana mau discuss kalau NPRA belum approve..


2021-06-01 11:20 | Report Abuse

Singapore to allow more vaccines approved by WHO

Speaking at the same press conference, Health Minister Ong Ye Kung revealed that the Ministry of Health (MOH) will be opening up access to other Covid-19 vaccines under the Special Access Route (SAR) in order to enhance the overall vaccination coverage for those who are unable to take the Pfizer or Moderna vaccine due to medical conditions, 

This differs from the Pandemic Special Access Route (PSAR), which the Health Science Authority has used to authorise the Pfizer and Moderna vaccines. 

MOH will allow the SAR to be used for the supply of Covid-19 vaccines that have been approved by the World Health Organisation (WHO) to be on their Emergency Use Listing (EUL). 

Such use of the SAR for these unregistered pandemic vaccines will be time-limited, for the duration of the pandemic. These vaccines include Johnson and Johnson, Sinopharm and AstraZenaca, in addition to the Pfizer and Moderna shots. 

These vaccines will be made available through the private healthcare sector, but the doctor administering the vaccine should discuss the risks and benefits of using vaccines not registered or authorised by HSA with the patient

Patients will also need to sign an informed consent form to acknowledge that they have discussed with their doctor and accept all responsibility for the risks. 

The Government will not subsidise vaccines administered under the SAR, and persons vaccinated under the SAR will not be eligible for the Vaccine Injury Financial Assistance Programme for Covid-19 Vaccination (VIFAP). 

“As more data becomes available, MOH will be able to determine if persons vaccinated under the SAR may be eligible for the same exemptions on testing, or public health restrictions, which may be accorded to individuals vaccinated under our national programme,” says MOH.


2021-05-28 12:31 | Report Abuse

Tq for panic selling


2021-05-27 19:30 | Report Abuse

Hopefully with Sabah assistance approval is faster


2021-05-25 15:15 | Report Abuse

really hard to break 0.095 aisshhh


2020-05-30 22:43 | Report Abuse

Bumi Armada

More provisions from Bumi Armada?

BUMI Armada Bhd, the service provider to oil and gas companies, has provided for no less than RM5.8bil as impairments for its assets since the financial year 2016. The bulk of the provisioning was taken up at the group level.

If anybody had thought that the company, which is owned by T. Ananda Krishnan, was done with provisioning for its assets, they were proven wrong. In the latest quarter results, the company sunk into the red due to the setting aside RM314mil for impairments for its offshore marine services (OMS) segment.

Bumi Armada has 35 vessels in its OMS segment where the utilisation rate is 56%. Out of the 35 vessels, three are subsea construction (SC) vessels while the rest are offshore service vessels (OSVs).

According to analysts, the provisions are mainly for the SC vessels that are lying idle without any charter in hand since early last year. The SC vessels are in the Caspian Sea where drilling activities have reduced significantly.
Fortunately for Bumi Armada, its floating production, storage and offloading (FPSO) assets are performing well. Bumi Armada wholly owns four FPSOs and co-owns three others.

It has one FPSO asset that is lying idle and up for sale. Fortunately, the company has completely provided for the FPSO asset that was due to be mobilised to an oil field offshore Australia. But there were disagreements and the FPSO Claire has returned to the custody of Bumi Armada. Hence, if any sale happens, it is a pure writeback for Bumi Armada.

The company is looking to dispose of the remaining OSVs because competition is keen and margins are narrow in that particular segment of the oil and gas industry. Even Petronas has urged the local players to consolidate but its calls have largely fallen on deaf ears.

The concern is Bumi Armada would have to provide more impairments as more disposals of OSVs take place.

Towards this end, some analysts have downgraded the stock to as low as 10 sen as they do not see any catalyst for earnings growth and are uncertain if the company has to make more provisions.


2019-12-03 22:55 | Report Abuse

tq uncle donald n uncle xi..hrp esk ada lelong for solarvest..


2019-06-17 17:08 | Report Abuse

tq to everyone pls continue sell for the rest of the week...hopefully 60 sen by this Friday


2019-05-22 01:24 | Report Abuse

Really hope for panic selling sampai limit down...boleh beli bila amat murah..lelong lelong hehehe...


2019-04-22 13:41 | Report Abuse

Ini stock memang bagus..dpt kontrak ka atau good qtr result pun rasanya memang tak akan naik..vele good for long term


2019-04-09 10:11 | Report Abuse

Ari ni xkan naiklah mayb tungu minyak 100 dollar baru naik...sapa suka hold hold hold x tau sampai bila bolehlah tambah


2019-04-09 07:46 | Report Abuse

Minyak naik again tapi adakah vele vele n sapng akn tdo lagi....abg n adik smua naik


2019-03-14 11:20 | Report Abuse

X boleh naik ni...kejap2 0.31 kejap2 0.315...


2019-03-05 10:29 | Report Abuse

Jatuhlah wahai azrb mau beli balik ni...


2019-03-01 09:13 | Report Abuse

Tq everyone very cheap .keep falling pls...


2019-02-28 19:00 | Report Abuse

Yes losses are going down hopefully they can extend their court order with creditors this March


2018-12-10 17:20 | Report Abuse

Pelik ari ni xde pulak berita pasal armada...media shd issue recycle story everyday so it can close at 10 sen ASAP


2018-11-22 19:11 | Report Abuse

Hrp2 sama mcm ni lagi esk..for that i tq all seller


2018-08-28 17:17 | Report Abuse

Tq everyone for keeping sape cheap price..pls continue again for tomorrow..


2018-08-24 17:12 | Report Abuse

Tq mkt good trsding today....


2018-07-31 23:28 | Report Abuse


....As for Singapore's push for a clear Malaysian stand on the status of the high speed rail, Azmin said he will provide the answer to that in the next few weeks, "once we have firmed all things up".


2018-07-26 09:57 | Report Abuse

Come on panic sellers you can do this...pls bring it down to 0.35


2018-07-12 09:03 | Report Abuse

Putrajaya approves continuation of LRT3 at a final cost of RM16.63 billion today...alhamdulillah...


2018-07-11 18:01 | Report Abuse

Tq mrcb teruskan dgn harga jatuh..makin murah makin bagus..